Streetbeat News

Price Targets

ELAN

Elanco Animal Health's stock (ELAN) is trading higher following Piper Sandler's decision to maintain a Neutral rating while increasing the price target from $11 to $12.

Portfolio Pulse from Benzinga Newsdesk

November 14, 2023 | 5:47 pm

VTGN

Stifel analyst Paul Matteis has initiated coverage on Vistagen Therapeutics (NASDAQ:VTGN) with a Buy rating and set a price target of $12.

Portfolio Pulse from Benzinga Newsdesk

November 14, 2023 | 5:47 pm

JOBY

Cantor Fitzgerald analyst Andres Sheppard has reiterated an Overweight rating on Joby Aviation (NYSE:JOBY) and maintained a $10 price target for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

November 14, 2023 | 5:38 pm

MVIS

Cantor Fitzgerald analyst Andres Sheppard has maintained a Neutral rating on Microvision (NASDAQ:MVIS) but has lowered the price target from $4 to $3.

Portfolio Pulse from Benzinga Newsdesk

November 14, 2023 | 5:37 pm

ELUT

Cantor Fitzgerald analyst Ross Osborn has maintained an Overweight rating on Elutia (NASDAQ:ELUT) but reduced the price target from $8 to $6.

Portfolio Pulse from Benzinga Newsdesk

November 14, 2023 | 5:31 pm

LFMD

Cantor Fitzgerald analyst Sarah James has maintained an Overweight rating on LifeMD (NASDAQ:LFMD) and increased the price target from $8 to $9.

Portfolio Pulse from Benzinga Newsdesk

November 14, 2023 | 5:19 pm

WULF

Cantor Fitzgerald analyst Josh Siegler has maintained an Overweight rating on TeraWulf (NASDAQ:WULF) but reduced the price target from $4 to $3.

Portfolio Pulse from Benzinga Newsdesk

November 14, 2023 | 5:17 pm

MDGL

JMP Securities analyst Jonathan Wolleben has reiterated a 'Market Outperform' rating on Madrigal Pharmaceuticals (NASDAQ:MDGL) and maintained a price target of $383.

Portfolio Pulse from Benzinga Newsdesk

November 14, 2023 | 5:14 pm

VRDN

RBC Capital analyst Gregory Renza has reiterated an Outperform rating on Viridian Therapeutics (NASDAQ:VRDN) and maintained a price target of $35.

Portfolio Pulse from Benzinga Newsdesk

November 14, 2023 | 5:09 pm

IGMS

RBC Capital analyst Brian Abrahams has maintained a 'Sector Perform' rating on IGM Biosciences (NASDAQ:IGMS) but has reduced the price target from $11 to $8.

Portfolio Pulse from Benzinga Newsdesk

November 14, 2023 | 5:06 pm